Bernstein Maintains a Hold on Bristol-Myers Squibb Company (BMY)

Bristol-Myers Squibb Company (NYSE:BMY) is one of the best large cap value stocks to buy now. In a report released on September 25, Courtney Breen from Bernstein maintained a Hold rating on Bristol-Myers Squibb Company (NYSE:BMY) without assigning a price target.

Bristol-Myers Squibb Company (NYSE:BMY) reported $12.3 billion in revenues in fiscal Q2 2025, with growth portfolio revenues of $6.6 billion, up 18%.

GAAP EPS for the quarter was $0.64, and non-GAAP EPS was $1.46.

Bristol-Myers Squibb Company (NYSE:BMY) also raised its 2025 revenue guidance to the range of ~$46.5 billion to $47.5 billion, and updated its non-GAAP EPS range to $6.35 to $6.65.

Bristol-Myers Squibb Company (NYSE:BMY) is a biopharmaceutical company that discovers, develops, and delivers advanced medicines for serious diseases. Its medicines fall into various therapeutic classes, including hematology, oncology, cardiovascular, immunology, and neuroscience.

While we acknowledge the potential of BMY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.